Monthly SubscribersLog InAccess Current IssueAccess Archived IssuesAccess Nanosphere AlertsAccess Special ReportsRenew SubscriptionContact EditorsFrequently Asked QuestionsNanotech ReportSubscribe to Nanotech ReportWhat is Nanotechnology? Download Sample ReportFeature ArticlesJosh Wolfe BioSubscriber TestimonialsWeekly Insider ELetterFree SignUpELetter ArchiveSample ELetterRecommended JobsNanotech Conferences About Josh Wolfe Josh is cofounder and Managing Partner of Lux Capital, focusing on investments in Nanotechnology. Josh is Senior Associate of the Foresight Institute for Nanotechnology, the Coordinator for the Institute of Molecular Manufacturings Prize in Computational Nanotechnology, cofounder of The NanoBusiness Alliance and member of the Cognitive Science Society. Josh is the author of The Nanotech Report and the monthly ForbesWolfe Nanotech Report.

Josh is Senior Associate of the Foresight Institute for Nanotechnology, the Coordinator for the Institute of Molecular Manufacturings Prize in Computational Nanotechnology, cofounder of The NanoBusiness Alliance and member of the Cognitive Science Society. Before forming Lux Capital, he worked in Salomon Smith Barneys Investment Banking group, where his experience included 4 billion hotel merger, and defense against an unsolicited LBO. Josh graduated with distinction from Cornell University with Josh is the author of The Nanotech Report and the monthly ForbesWolfe Nanotech Report.

Prior to venturing into the financial world, Josh conducted and published cutting edge AIDSimmunopathology research in Cell Vision and The Journal of Leukocyte Biology, leading medicalimmunology journals. Josh is the author of The Nanotech Report and the monthly ForbesWolfe Nanotech Report. Josh has also worked in capital markets while at Merrill Lynch on its Financial Futures & OptionsGovernment Strategy desk and at Prudential Securities in its Municipal Finance department. Josh has been an invited guest lecturer and panelist at Harvard, Yale, Wharton, Columbia, University of Virginia, Polytechnic, New York Business Forums, Merrill Lynch, NERASBIC and the Foresight Institute.

Prior to venturing into the financial world, Josh conducted and published cutting edge AIDSimmunopathology research in Cell Vision and The Journal of Leukocyte Biology, leading medicalimmunology journals. Josh has also worked in capital markets while at Merrill Lynch on its Financial Futures & OptionsGovernment Strategy desk and at Prudential Securities in its Municipal Finance department.

Josh is the author of The Nanotech Report and the monthly ForbesWolfe Nanotech Report. Monthly SubscribersLog InAccess Current IssueAccess Archived IssuesAccess Nanosphere AlertsAccess Special ReportsRenew SubscriptionContact EditorsFrequently Asked QuestionsNanotech ReportSubscribe to Nanotech ReportWhat is Nanotechnology?